Spire Healthcare Group plc account plan
UK Private Healthcare Services
At a glance
Spire Healthcare is a UK independent hospital and primary care group: 38 hospitals, £1,579.8m FY2025 revenue, 17,800 colleagues.
Spire Healthcare Group plc is a large independent UK healthcare group operating across England, Wales and Scotland, with 38 hospitals, over 60 clinics and almost 100 clinical sites in primary care. It cared for 1.36m+ people in 2025, employs 17,800 colleagues and works with over 8,800 consultants. Private patients were 65% of group revenue (PMI 43%, self-pay 21%) and the NHS 31%. FY2025 revenue was £1,579.8m (+4.5%), adjusted EBITDA £268.6m and operating profit £122.6m. A Toscafund-led consortium has made a recommended final offer for the company.
Business units
Hospitals
92% of revenue; £1,446.1m FY2025 revenue38 private hospitals treating insured, self-pay and NHS patients, with 43.4% of the addressable full-service hospital market and 42.5% of private hip and knee procedures in the year to March 2026. H1 2026 revenue fell 1.6% to £720.6m as NHS revenue dropped 14.3%, cutting the margin to 14.8%.
Primary Care Services
8% of revenue; £133.7m FY2025 revenueVita Health Group, The Doctors Clinic Group (Spire Occupational Health, London Doctors Clinic), Spire GP, Spire Clinics and Spire Mental Health, covering talking therapies, physiotherapy, occupational health and GP services for the NHS, employers and consumers. H1 2026 revenue rose 8.1% to £72.1m. Vita Health Group is led by CEO Derrick Farrell.
Strategic priorities
- Transformation savings
- Centralise, standardise, digitalise and enable AI: £30m of new savings in 2025 and a savings target above £30m for 2026 to at least offset the Q1 NHS shortfall.
- Private payer growth
- Mid to high single digit private revenue growth in 2026, supported by record brand awareness and AI-optimised local self-pay pricing.
- Website and CRM
- A new website and CRM integrating all patient types across primary and secondary care is a named 2026 priority.
- Scale primary care
- Take primary care from about £10 million of EBITDA to £40 million in the medium term through organic growth, new NHS contracts, new clinics and small M&A, with no more than £50 million of capex.
- Capex discipline
- Capex reduced about 30% to £78.5m in 2026 as the estate is well invested; only a few capex-light clinics are planned.
Latest results
In H1 2026 (six months to 30 June 2026) revenue was £792.7m, down 0.8% comparable, and adjusted EBITDA fell 16.6% to £112.4m (14.2% margin), with a statutory loss before tax of £14.8m. Self-pay revenue rose 4.5% and PMI 3.1%, but NHS revenue fell 14.3% (Q1 down 24.9%, Q2 down 3.2% after commissioning plans reset in April 2026). Adjusted free cash flow rose 35.3% to £20.7m, net bank debt was £337.8m (leverage 2.4x) and no interim dividend was paid. FY26 adjusted EBITDA is targeted broadly in line with FY25.
Investments and deals
- Patient support centres
- Three centres in Brentwood, Cardiff and Seaham absorbed administration for 36 hospitals and lifted call answer rates above 95% from 60%.
- Robotics and AI imaging
- Over 30 robots installed and AI on MRI scanners in 21 hospitals halving scan times.
- Primary care acquisitions
- Acorn Health and Physiolistic were acquired at mid-single-digit multiples, adding to £8 million of new annual contract revenue including John Lewis Partnership.
- Bupa partnership
- A new four-year strategic partnership with Bupa covering cancer specialist centres, MSK rapid access and a gynaecology specialist centre.
Challenges and risks
- NHS commissioning slowdown
- NHS budgetary restrictions cut commissioning to the independent sector from late 2025; NHS revenue fell 14.3% in H1 2026 and the provisional 2026 NHS tariff is close to 0%.
- Labour cost inflation
- National Insurance and National Minimum Wage increases weigh on costs while the NHS tariff uplift falls short of inflation.
- Ownership uncertainty
- The strategic review led to a recommended final offer from a Toscafund-led consortium, and the H1 2026 report carries a material going-concern uncertainty disclosure.
- Leadership transition
- Justin Ash retired as CEO on 5 September 2026; Sir David Sloman is Interim CEO.
- PMI volume pressure
- PMI volumes dipped as insurers tighten claims and younger insured members use primary care.
What leadership says
“the biggest year of change yet for our business”
“the business we think is in the best position it has ever been in to navigate a very dynamic environment”
Where a supplier can help
- CRM and digital front door
- The new website and CRM integrating all patient types across primary and secondary care is a named priority, a direct opening for CRM, web and patient-engagement suppliers.
- Automation behind transformation savings
- A savings target above £30m for 2026 and the centralise-digitalise-AI programme fit P2P automation, AI scheduling and contact-centre tooling.
- Employer health services
- Growth in workplace health and occupational health under Spire for Business suits partners selling to employers or into occupational health workflows.
- Cyber security
- Cyber security is one of the 15 principal risks as digital platforms expand, supporting security offers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Spire Healthcare Group plc?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report and Accounts 2025
- Spire Healthcare Group plc is a large independent UK healthcare group operating across England, Wales and Scotland: 38 hospitals, over 60 clinics and almost 100 clinical sites in primary care; it cared for 1.36m+ people in 2025 and employs 17,800 colleagues, working with over 8,800 consultants.
- FY2025 (year to 31 December 2025): revenue £1,579.8m, up 4.5%; adjusted EBITDA £268.6m, up 3.3%; operating profit £122.6m, down 12.3%; adjusted free cash flow £64.3m; ROCE 8.0%; dividend 1.5p per share (2024: 2.3p).
- Two segments: Hospitals (92% of revenue; revenue £1,446.1m, adjusted EBITDA margin 17.9%) and Primary Care Services (8%; revenue £133.7m, up 10.5%, adjusted EBITDA £9.8m), covering Vita Health Group, The Doctors Clinic Group (Spire Occupational Health, London Doctors Clinic), Spire GP, Spire Clinics and Spire Mental Health.
- Payor mix: private patients 65% of group revenue (PMI 43%, self-pay 21%), NHS 31%, other (employers and non-patient revenue) 4%; contracts with all major insurers (Aviva, AXA Health, Bupa, Vitality Health).
- Transformation programme (centralise, standardise, digitalise, enable AI) delivered £30m of new savings in 2025; three patient support centres (Brentwood, Cardiff, Seaham) absorbed administration for 36 hospitals and lifted call answer rates above 95% from 60%; around 400 permanent hospital roles were removed.
- Key headwind: a slowdown in NHS commissioning to the independent sector late in 2025 owing to NHS budgetary restrictions, plus National Insurance and National Minimum Wage increases; the proposed 2026-27 NHS tariff uplift falls short of inflation.
- Strategic review announced September 2025, considering a potential sale of the company, value generation from the hospital property estate and changes to plans; medium-term targets withheld while it runs.
- 2026 priorities: maximise patient support centres, a new website and CRM system, tight operational control, organic growth in workplace health and integration of primary care acquisitions; capex reduced about 30% to £78.5m as the estate is well invested.
- Buying signals: investment in digital, data platforms, AI (MRI image enhancement in 21 hospitals), robotics (29 robots), CRM, website, P2P automation and cyber security; 15 principal risks including cyber security, transformation execution, NHS market dynamics and workforce.
- Half year results for the six months ended 30 June 2026
- H1 2026 (six months to 30 June 2026): revenue £792.7m (H1 2025: £796.7m), down 0.8% comparable; adjusted EBITDA down 16.6% comparable to £112.4m; adjusted EBITDA margin 14.2%; statutory loss before tax £14.8m.
- Hospitals: revenue down 1.6% to £720.6m, adjusted EBITDA £106.9m, margin 14.8% (H1 2025: 17.8%); self-pay revenue up 4.5%, PMI up 3.1%, NHS down 14.3% (Q1 down 24.9%, Q2 down 3.2% after commissioning plans reset in April 2026).
- Over 95% of Indicative Activity Plan related NHS revenue for the 2026/27 NHS financial year agreed; average revenue per case up 4.3%.
- Market share: 43.4% of the addressable full-service hospital market and 42.5% of private hip and knee procedures in the year to March 2026.
- Primary Care: revenue up 8.1% to £72.1m, adjusted EBITDA up 23.7% to £5.5m, margin 7.6%; John Lewis Partnership and Derby talking therapies contracts delivering.
- New four-year strategic partnership with Bupa (cancer specialist centres, MSK rapid access, a gynaecology specialist centre); Team GB Official Healthcare Services Partner to 2028; over 30 robots installed.
- Cash: adjusted FCF up 35.3% to £20.7m, capex down 29.1% to £36.3m, net bank debt £337.8m, leverage 2.4x; no interim dividend.
- Leadership and ownership: Justin Ash retired as CEO on 5 September 2026, Sir David Sloman is Interim CEO and Debbie White Chair; a Toscafund-led consortium (Tulip UK Bidco, with THCP and Ares) made a recommended final offer, creating a material going-concern uncertainty disclosure.
- Outlook: FY26 adjusted EBITDA targeted broadly in line with FY25.
- Spire Healthcare full year 2025 results call (transcript)
- Justin Ash (CEO) and Harbant Samra (CFO) presented FY2025 results on 5 March 2026: revenue up 4.5%, adjusted EBITDA up 3.2% to £268.6m, adjusted free cash flow up 64.9% to £64.3m, £30m of transformation savings delivered.
- Ash called 2025 "the biggest year of change yet for our business": three patient support centres now answer around 95% of calls versus 60% before, 29 surgical robots, AI on MRI scanners in 21 hospitals halving scan times.
- Brand and self-pay: unprompted and prompted awareness at record 35% and 80%, consideration up 6% to 61%; AI used to optimise local self-pay pricing; self-pay returned to positive volume growth.
- NHS: commissioning slowdown means NHS revenue expected down about 25% in Q1 2026; base planning assumption Q2-Q4 NHS revenue down 5-10%; provisional 2026 NHS tariff close to 0%.
- 2026 guidance: adjusted EBITDA broadly in line with 2025; private revenue growth mid to high single digit; savings target above £30m to at least offset the Q1 NHS shortfall; limited M&A.
- Priorities: private payer growth, a new website and CRM integrating all patient types across primary and secondary care, employer market, a few capex-light clinics, capex discipline.
- Strategic review (possible sale, property estate value) ongoing; Takeover Panel rules limit what management can say.
- Spire Healthcare half year 2025 results call (transcript)
- Justin Ash (CEO) and Harbant Samra (CFO) presented H1 2025 results on 31 July 2025: revenue up 4.9%, adjusted EBITDA up 2.8% to £133 million, savings of more than £10 million in H1 and a further £20 million planned for H2.
- Ash: "the business we think is in the best position it has ever been in to navigate a very dynamic environment"; strategy built on a diversified three-payer model, transformation, scaling primary care and quality.
- Transformation: around 400 permanent roles reduced; three patient support centres (Brentwood, Cardiff, Seaham) answering 50% more patient calls with approximately 10% fewer staff; AI expected to help match patients to consultants.
- Hospitals: revenue £732.3 million; NHS revenue up over 16%; orthopaedics over 60% of NHS admissions; higher-margin procedures approximately 38% of private admissions.
- Primary care: £10m to £40m EBITDA ambition with no more than £50 million of capex; Acorn Health and Physiolistic acquired at mid-single-digit multiples, £8 million of new annual contract revenue incl. John Lewis Partnership.
- Freehold portfolio of 19 hospital properties valued at more than £1.4 billion; ROCE target above 10%.
- PMI volumes dipped as insurers tighten claims and younger insured members use primary care; Ash sees that shift as a reason for Spire's primary care strategy.
- Spire Healthcare primary care roundtable (transcript)
- Primary care roundtable for investors on 20 May 2025, led by Derrick Farrell (CEO, Vita Health Group) and Peter Corfield (Chief Commercial Officer), hosted by IR director Amie Gramlick.
- Ambition: take primary care from about £10 million of EBITDA (within a group of about £260 million) to £40 million in the medium term, through organic growth, new NHS contracts, new clinics and small M&A.
- Corfield sizes the UK primary care and hospital markets at about £6 billion each; segment growth rates: occupational health 6%, GP services 10%, talking therapies 10%, physiotherapy 4%.
- Vita was 75% NHS and 25% corporate when acquired; Vita for NHS is about £70 million of revenue; occupational health including Vita about £35 million; Spire is the largest talking therapies business in the UK.
- Organisation by customer group (NHS, Spire for Business, B2C clinics) across talking therapies, physio, occupational health and GP; new services planned in children's mental health and neurodiversity.
- Corporate return-to-work rates in the mid-90s percent; occupational health split between health surveillance (40-50%) and sickness absence management.
- Clinics: small physio/GP sites at about £30,000-40,000 a room; up to three or four clinics around each hospital; site selection uses the SPOTS gravity model; a new CRM to manage all patients across the pathway.
Questions about Spire Healthcare Group plc
What does Spire Healthcare do?
Spire runs 38 private hospitals and over 60 clinics in England, Wales and Scotland, plus primary care services such as talking therapies, physiotherapy, occupational health and GP care, for insured, self-pay and NHS patients.
What is Spire Healthcare's revenue?
FY2025 revenue was £1,579.8m with adjusted EBITDA of £268.6m. H1 2026 revenue was £792.7m.
How many employees does Spire Healthcare have?
Spire employs 17,800 colleagues and works with over 8,800 consultants.
Who leads Spire Healthcare?
Sir David Sloman is Interim CEO since Justin Ash retired on 5 September 2026, and Debbie White is Chair.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)